Lactic Acid Bacteria Strains for Hepatoprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for liver protection are inadequate in addressing oxidative stress and inflammation, particularly in conditions like alcoholic hepatitis and non-alcoholic fatty liver disease, with few effective strains of lactic acid bacteria identified.
Innovation Solution
A food and pharmaceutical composition comprising specific strains of active or inactive lactic acid bacteria, including TSP05 strain of Lactobacillus plantarum, TSF331 strain of Lactobacillus fermentum, and TSR332 strain of Lactobacillus reuteri, which are deposited in the China General Microbiological Culture Collection Center, to prevent liver damage from oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional liver protection treatments are used, then general liver support is provided, but they are inadequate in addressing oxidative stress and inflammation
Solution Approach 1:
The patent changes the biological parameter by introducing specific probiotic strains (Lactobacillus plantarum TSP05, Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332) that possess hepatoprotective properties. These strains modify the gut-liver axis parameters, reducing oxidative stress and inflammation through microbial metabolism products and immune modulation, thereby addressing the inadequacy of conventional treatments.
Solution Approach 2:
The probiotic bacteria act as intermediaries between the gut and liver. They colonize the gut, produce beneficial metabolites (short-chain fatty acids, antioxidants), and modulate systemic inflammation, thereby indirectly protecting the liver from oxidative stress and inflammatory damage without directly targeting liver tissue.
2Adaptability or versatility
If more lactic acid bacteria strains are tested, then potentially effective hepatoprotective strains may be found, but the complexity and time of research increases
Solution Approach 1:
The patent segments the broad search space of lactic acid bacteria into specific genera and species groups (Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus reuteri) based on preliminary screening results. This segmentation allows focused evaluation of promising strains rather than testing all possible lactic acid bacteria, reducing research complexity while maintaining versatility.
Solution Approach 2:
The patent performs preliminary screening and selection of lactic acid bacteria strains based on their probiotic characteristics and potential hepatoprotective properties before conducting detailed efficacy studies. This preliminary action identifies the most promising candidates (TSP05, TSF331, TSR332), reducing the overall research complexity by eliminating less promising strains early in the development process.
Data Source
AI summary
At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.